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Sudden cardiac death (SCD) is one of the most com-
mon causes of death in Western countries, and the
implantable cardioverter deﬁbrillator (ICD) is the
treatment which has the most striking preventive
impact in high-risk patients with heart disease. Rand-
omized clinical trials have produced strong evidence
that prophylactic use of ICDs in appropriately selected
patients is associated with improved survival at 2 to
5 years of follow-up; these ﬁndings regard patients
with previous ventricular tachyarrhythmias (secondary
prevention of SCD), and also patients with a high-risk
proﬁle but no previous ventricular tachyarrhythmias
(so-called primary prevention) [1,2]. During the last
few years, increasingly broad indications for ICD ther-
apy have been incorporated into consensus guidelines
on the management of both arrhythmia and heart fail-
ure [3]. At the same time, major concerns have been
voiced about the ﬁnancial implications of wide adop-
tion of ICDs [1], in view of the high number of poten-
tial candidates, particularly among elderly heart failure
patients. The ICD has traditionally been perceived as a
ﬁnancially burdensome form of treatment. This is due
to the high up-front cost of the device (currently at
least $15,000 in the United States), coupled with
delayed evidence of beneﬁt (if any) in individual
patients. As a consequence, great interest has been
focused on economic studies of the use of ICDs in SCD
prevention. In particular, a series of cost-effectiveness
and cost-utility analyses based on trials or decision
models have been performed and compared [4,5].
In this issue of Value in Health, Caro et al. [6]
present probably the ﬁrst available cost-beneﬁt analy-
sis on ICDs in primary prevention. The investigators
performed a comparison of cost-beneﬁt values esti-
mated for ICD versus prophylactic treatment with the
most prominent antiarrhythmic drug, amiodarone.
This modeling study was based on discrete event sim-
ulation of data derived from a major, ground-breaking
clinical trial (Sudden Cardiac Death in Heart Failure
Trial, which compared the efﬁcacy of ICDs and amio-
darone for the primary prevention of SCD in heart fail-
ure patients), together with data from an important
meta-analysis  of  more  than  6500  patients  enrolled
in randomized clinical trials on amiodarone. The
authors’ conclusion that in “countries where society
values a life at more than more than €2 million, ICDs
are a worthwhile investment compared with amiodar-
one for primary prevention” raises important issues on
the implications of cost-beneﬁt estimates in this par-
ticular clinical and epidemiological setting.
The potential for expansion of ICD use raises difﬁ-
cult questions regarding the “worth” of implementing
this therapeutic strategy in clinical practice. In a soci-
etal perspective, the use of cost-beneﬁt analysis to
assess allocative efﬁciency appears topical, especially
in the context of ﬁxed health-care budgets. This
approach, however, has been criticized by nonecono-
mists who have viewed it as a sort of “monetarization
machine” [7]. Attaching a monetary value to life for a
cost-beneﬁt analysis is a delicate task, and the speciﬁc
methods and values applied will always be open to
debate. In the study by Caro et al. [6], a nation-speciﬁc
monetary value was assigned to each life saved, ap-
plying the willingness-to-pay approach used in the
transportation and trafﬁc safety or environmental
protection ﬁelds. When applied to heart failure, this
approach may prompt some reservations when the
same value per life used for healthy, active, middle-
aged individuals is transferred to elderly patients in a
severely compromised state of health. Cost-beneﬁt and
cost-effectiveness analyses clearly address somewhat
different questions [8], and analogous reservations
have also been raised for cost-effectiveness evaluations
regarding their true ability to express the beneﬁts
achievable in elderly people [9].
Some reﬂections could be in order regarding the
application of economic evaluations based on cost-
beneﬁt or cost-effectiveness estimates to the speciﬁc
setting of ICDs in elderly patients with heart failure.
Older age and comorbidities are obvious determinants
of life expectancy. This is reﬂected in the model con-
structed by Caro et al. [6], where after 70 years of age
the annual risk of nonsudden cardiac death appears to
exceed the risk of severe arrhythmia potentially caus-
ing SCD. This translates into a progressive reduction
of the expected clinical beneﬁts of ICD therapy with
increasing age, when competing causes of death (i.e.,
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other than SCD) become more relevant as deter-
minants of prognosis. Indeed, sensitivity analysis of
cost-effectiveness studies indicates that various factors
associated with increasing old age are associated with
less favorable ICD incremental cost-effectiveness esti-
mates [4]. In this respect, the results of a cost-beneﬁt
evaluation of ICD use, such as that by Caro et al. (who
mention only “slightly less favorable results” beyond
70 years of age) [6], may not be directly applicable to
the speciﬁc setting of elderly patients. As suggested by
the authors in their discussion, a downward adjust-
ment of the monetary value of a patient’s life might be
appropriate to reﬂect the impact of age, comorbidities,
and actual life expectancy.
In the wake of landmark clinical trials demonstrat-
ing the efﬁcacy of ICDs in appropriately selected
patient populations and of economic analyses support-
ing their cost-effectiveness, the timely cost-beneﬁt
study reported by Caro et al. [6] further challenges the
widespread assumption that ICDs should be viewed as
a worrying ﬁnancial burden for society. On the con-
trary, ICDs could turn out to be a worthwhile invest-
ment. Nevertheless, for budget-constrained health-care
systems, the real affordability of an SCD prevention
strategy based on widespread implementation of ICDs
in line with current guidelines remains uncertain. This
problem especially regards the potential inclusion of
elderly heart failure patients, who constitute an
increasing burden for health-care systems [10], in
whom ICD implantation may be associated with less
favorable cost-beneﬁt and cost-effectiveness estimates.
Because elderly patients are not a homogeneous group,
an important way of improving cost-beneﬁt and cost-
effectiveness could be the reﬁnement of selection crite-
ria for ICD candidacy (i.e., by selecting patients at high
risk of arrhythmic death and low risk of competing
nonarrhythmic death) [11]. This approach should
allow us to optimize the clinical beneﬁts delivered to
patients and also the investment for society. To pursue
this aim, further clinical and economic studies speciﬁ-
cally focusing on elderly patient populations could be
highly relevant.
I am grateful to Robin MT Cooke for writing assistance.
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